Revelation Biosciences, Inc. announced that it has entered into a security purchase agreement for the issuance of one Series A Preferred Stock, par value $0.001 per share at a price of $5,000 per share for gross proceeds of $5,000 on December 19, 2022. The transaction included participation from Chief Executive Officer James Rolke of the company. The securities represented in the transaction have not been registered under 4(a)(2) of the Securities Act of 1933, as amended.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.91 USD | -2.04% | -13.17% | -87.28% |
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-87.28% | 3.18M | |
+33.15% | 49.46B | |
+1.94% | 42.58B | |
+49.11% | 42.49B | |
-4.22% | 29.09B | |
+12.21% | 26.61B | |
-23.07% | 18.64B | |
+8.38% | 13.16B | |
+30.32% | 12.55B | |
+24.17% | 12.1B |
- Stock Market
- Equities
- REVB Stock
- News Revelation Biosciences, Inc.
- Revelation Biosciences, Inc. announced that it has received $0.005 million in funding